Use of oncolytic viruses for the eradication of drug-resistant cancer cells

Journal of the Royal Society Interface

Volumn 6, Issue 1, 2009, Pages 179-186

  Wodarz, Dominik ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apparent competition; Mathematical models; Oncolytic virus therapy

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; COMPETITION; CYTOLOGY; FUNCTIONS; MATHEMATICAL MODELS; MICROORGANISMS; VIRUSES;

APPARENT COMPETITION; CANCER CELLS; CANCER.; CELL POPULATIONS; CLINICAL TRIALS; COMPUTATIONAL FRAMEWORKS; DRUG RESISTANCES; MOLECULE INHIBITORS; ONCOLYTIC VIRUS THERAPY; PROMISING THERAPIES; RESISTANT MUTANTS; SEQUENTIAL COMBINATIONS;

DRUG THERAPY;

ONCOLYTIC VIRUS;

ARTICLE; CANCER CELL; CELL POPULATION; CELL SURVIVAL; ERADICATION THERAPY; ONCOLYTIC VIROTHERAPY;

EID: 58149170606     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2008.0191     Document Type: Article

References (55)

1. Anderson, R. M. & May, R. M. 1978 Regulation and stability of host-parasite population interactions: I. Regulatory processes. J. Anim. Ecol. 47, 249-267.
2. Antonovics, J., Iwasa, Y. & Hassell, M. P. 1995 A generalized model of parasitoid, venereal, and vector-based transmission processes. Am. Nat. 145, 661-675.
3. Back, N. K., Nijhuis, M., Keulen, W., Boucher, C. A., Oude Essink, B. O., van Kuilenburg, A. B., van Gennip, A. H. & Berkhout, B. 1996 Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. Embo J. 15, 4040-4049.
4. Barnes, D. J. & Melo, J. V. 2006 Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 5, 2862-2866.
5. Begon, M., Hazel, S. M., Baxby, D., Bown, K., Cavanagh, R., Chantrey, J., Jones, T. & Bennett, M. 1999 Transmission dynamics of a zoonotic pathogen within and between wildlife host species. Proc. R. Soc. B 266, 1939-1945.
6. Bell, J. C. 2007 Oncolytic viruses: what's next? Curr. Cancer Drug Targets 7, 127-131.
7. Bell, J. C., Lichty, B. & Stojdl, D. 2003 Getting oncolytic virus therapies off the ground. Cancer Cell 4, 7-11.
8. Blagosklonny, M. V. 2002 STI-571 must select for drugresistant cells but 'no cell breathes fire out of its nostrils like a dragon'. Leukemia 16, 570-572.
9. Bonsall, M. B. & Hassell, M. P. 2000 The effects of metapopulation structure on indirect interactions in host-parasitoid assemblages. Proc. R. Soc. B 267, 2207-2212.
10. Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y. & Sawyers, C. L. 2005 Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl Acad. Sci. USA 102, 3395-3400.
11. Crompton, A. M. & Kirn, D. H. 2007 From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr. Cancer Drug Targets 7, 133-139.
12. Davis, J. J. & Fang, B. 2005 Oncolytic virotherapy for cancer treatment: challenges and solutions. J. Gene Med. 7, 1380-1389.
13. Deininger, M. W. & Druker, B. J. 2003 Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55, 401-423.
14. Deininger, M. W., Goldman, J. M. & Melo, J. V. 2000 The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
15. Diekmann, O. & Kretzschmar, M. 1991 Patterns in the effects of infectious diseases on population growth. J. Math. Biol. 29, 539-570.
16. Druker, B. J. 2004 Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30.
17. Goldman, J. M. & Melo, J. V. 2003 Chronic myeloid leukemia -advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451-1464.
18. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N. & Sawyers, C. L. 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
19. Greenman, J. V. & Hudson, P. J. 1999 Host exclusion and coexistence in apparent and direct competition: an application of bifurcation theory. Theor. Popul. Biol. 56, 48-64.
20. Greenman, J. V. & Hudson, P. J. 2000 Parasite-mediated and direct competition in a two-host shared macroparasite system. Theor. Popul. Biol. 57, 13-34.
21. Guillemard, V. & Saragovi, H. U. 2004 Novel approaches for targeted cancer therapy. Curr. Cancer Drug Targets 4, 313-326.
22. Hassell, M. P. & Bonsall, M. B. 1997 Apparent competition structures ecological assemblages. Nature 388, 371-373.
23. Heesterbeek, J. A. & Metz, J. A. 1993 The saturating contact rate in marriage- and epidemic models. J. Math. Biol. 31, 529-539.
24. Holt, R. D. 1977 Predation, apparent competition and the structure of prey communities. Theor. Popul. Biol. 12, 197-229.
25. Holyoake, T., Jiang, X., Eaves, C. & Eaves, A. 1999 Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056-2064.
26. Holyoake, T. L., Jiang, X., Jorgensen, H. G., Graham, S., Alcorn, M. J., Laird, C., Eaves, A. C. & Eaves, C. J. 2001 Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97, 720-728.
27. Kaplan, J. M. 2005 Adenovirus-based cancer gene therapy. Curr. Gene Ther. 5, 595-605.
28. Kelly, E. & Russell, S. J. 2007 History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651-659.
29. Kirn, D. H. & McCormick, F. 1996 Replicating viruses as selective cancer therapeutics. Mol. Med. Today 2, 519-527.
30. Komarova, N. L. & Wodarz, D. 2005 Drug resistance in cancer: principles of emergence and prevention. Proc. Natl Acad. Sci. USA 102, 9714-9719.
31. Lorence, R. M., Pecora, A. L., Major, P. P., Hotte, S. J., Laurie, S. A., Roberts, M. S., Groene, W. S. & Bamat, M. K. 2003 Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther. 5, 618-624.
32. May, R. M. & Anderson, R. M. 1987 Transmission dynamics of HIV infection. Nature 326, 137-142.
33. McCallum, H., Barlow, N. & Hone, J. 2001 How should pathogen transmission be modelled? Trends Ecol. Evol. 16, 295-300.
34. McCormick, F. 2003 Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther. 2, S157-S160.
35. McCormick, F. 2005 Future prospects for oncolytic therapy. Oncogene 24, 7817-7819.
36. Melo, J. V. & Barnes, D. J. 2007 Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7, 441-453.
37. Melo, J. V., Hughes, T. P. & Apperley, J. F. 2003 Chronic myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program 132-152.
38. Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, P., Gulnik, S. & Boucher, C. A. 1999 Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. Aids 13, 2349-2359.
39. Novozhilov, A. S., Berezovskaya, F. S., Koonin, E. V. & Karev, G. P. 2006 Mathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models. Biol. Direct 1, 6.
40. O'Dwyer, M. E., Mauro, M. J. & Druker, B. J. 2002 Recent advancements in the treatment of chronic myelogenous leukemia. Annu. Rev. Med. 53, 369-381.
41. O'Shea, C. C. 2005 Viruses-seeking and destroying the tumor program. Oncogene 24, 7640-7655.
42. Parato, K. A., Senger, D., Forsyth, P. A. & Bell, J. C. 2005 Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5, 965-976.
43. Post, D. E., Shim, H., Toussaint-Smith, E. & Van Meir, E. G. 2005 Cancer scene investigation: how a cold virus became a tumor killer. Future Oncol. 1, 247-258.
44. Roberts, M. S., Lorence, R. M., Groene, W. S. & Bamat, M. K. 2006 Naturally oncolytic viruses. Curr. Opin. Mol. Ther. 8, 314-321.
45. Sawyers, C. L. 1999 Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340.
46. Shannon, K. M. 2002 Resistance in the land of molecular cancer therapeutics. Cancer Cell 2, 99-102.
47. Tipping, A. J., Mahon, F. X., Lagarde, V., Goldman, J. M. & Melo, J. V. 2001 Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood 98, 3864-3867.
48. Tlsty, T. D., Margolin, B. H. & Lum, K. 1989 Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbruck fluctuation analysis. Proc. Natl Acad. Sci. USA 86, 9441-9445.
49. Vaha-Koskela, M. J., Heikkila, J. E. & Hinkkanen, A. E. 2007 Oncolytic viruses in cancer therapy. Cancer Lett. 254, 178-216.
50. Wodarz, D. 2001 Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res. 61, 3501-3507.
51. Wodarz, D. 2003 Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum. Gene Ther. 14, 153-159.
52. Wodarz, D. 2004 Computational approaches to study oncolytic virus therapy: insights and challenges. Gene Ther. Mol. Biol. 8, 137-146.
53. Wodarz, D. & Komarova, N. L. 2005 Emergence and prevention of resistance against small molecule inhibitors. Semin. Cancer Biol. 15, 506-514.
54. Yee, K. W. & Keating, A. 2003 Advances in targeted therapy for chronic myeloid leukemia. Expert Rev. Anticancer Ther. 3, 295-310.
55. Zurakowski, R. & Wodarz, D. 2007 Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus. J. Theor. Biol. 245, 1-8.